EXHIBIT A
JOINT FILING AGREEMENT
The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Ordinary Share, par value £0.003 per share, of Mereo BioPharma Group plc is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 14, 2023.
| OrbiMed Advisors LLC | |||
| By: | /s/ Carl L. Gordon | ||
| Name: | Carl L. Gordon | ||
| Title: | Member | ||
| OrbiMed Capital LLC | |||
| By: | /s/ Carl L. Gordon | ||
| Name: | Carl L. Gordon | ||
| Title: | Member | ||
OrbiMed Capital GP VII LLC By: OrbiMed Advisors LLC, its Managing Member | |||
| By: | /s/ Carl L. Gordon | ||
| Name: | Carl L. Gordon | ||
| Title: | Member of OrbiMed Advisors LLC | ||